Scientific Posters , Pediatrics

EuPFI 2019 Poster: Development of a Paediatric Oral Suspension of a Novel Drug for the Treatment of Kidney Disease

10 September 2019
Overview

This development program aimed to develop an aqueous,multi-dose oral suspension formulation of a novel drug candidate at a concentration of 20mg/ml that would be appropriate for the treatment of kidney disease in pediatric patients aged 2 years and older. A liquid formulation was favored over a coated granule formulation. 

Download Quotient Sciences' poster, 'EuPFI 2019 Poster-Development of a Paediatric Oral Suspension of a Novel Drug for the Treatment of Kidney Disease'.

Download
Date
10 September 2019
Ask The Experts

Pediatric drug development questions? Get answers from our team.

Have a question about your pediatric drug program? Ask a member of our team about our capabilities for drug product clinical manufacturing, commercial manufacturing, or clinical testing to keep your pediatric drug program on-track.

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Nazim Kanji

Executive Director, Pediatric Services

Nazim Kanji has over 25 years of experience in the pharmaceutical and consumer healthcare industries, where he has worked in produ...

About Nazim
Dr. Asma Patel

VP, Integrated Development Services

Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...

About Asma
Get in touch
Humanity can't afford to wait, so neither can we.